Aug 26, 2025 • Benzinga
NEUTRAL
What's Going On With ImmunityBio Shares Tuesday? - ImmunityBio ( NASDAQ:IBRX )
ImmunityBio reports all five patients with recurrent glioblastoma show disease control, including two with near complete responses. The company says it is advancing to a Phase 2 trial after what it calls highly encouraging early results. See the 6X seasonal strategy set to target this fall's ...
Aug 18, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
MIRAMAR, Fla., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- HCW Biologics Inc. ( the "Company" or "HCW Biologics" ) ( NASDAQ: HCWB ) , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation ...
Aug 06, 2025 • Motley Fool
NEUTRAL
IBRX Sales Soar 2,540%
ImmunityBio ( NASDAQ:IBRX ) , a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue ( GAAP ) jumped to $26.4 million, soundly beating analyst GAAP revenue estimates of $23.15 million, as commercial sales of the immunotherapy ...
Aug 05, 2025 • Zacks Commentary
NEUTRAL
ImmunityBio ( IBRX ) Reports Q2 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 22, 2025 • Benzinga
NEUTRAL
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - ImmunityBio ( NASDAQ:IBRX )
Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year,
May 22, 2025 • Zacks Commentary
NEUTRAL
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.